lebrikizumab vs tralokinumab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Atopic Dermatitis

Shared mechanism: IL-13 · full Atopic Dermatitis pipeline

lebrikizumab · Ebglyss

Marketed by Eli Lilly and partners

Approved in Atopic Dermatitismonoclonal antibody
Reliable signal

NCT04146363 · Phase 3 · completed

The randomized, quadruple-masked, placebo-controlled trial enrolled 424 participants and evaluated clinical skin outcomes as its two primary endpoints. At Week 16, both endpoints were met: IGA 0/1 response was 43.1% with lebrikizumab versus 12.7% with placebo (p<0.000001), and EASI-75 response was 58.8% versus 16.2% (p<0.000001).

Next expected readout: April 2027 · NCT06526182 (registry estimate)

Reported efficacy

Percentage of Participants With an Investigator Global Assessment (IGA) Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 16; Percentage of Participants Achieving Eczema Area And Severity Index (EASI-75) (≥75% Reduction in EASI Score) From Baseline to Week 16: Percentage of Participants With an Investigator Global Assessment (IGA) Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 16 (Baseline to Week 16): Lebrikizumab Q2W 33.2% (95% CI 27.5 to 38.9) vs Placebo 10.8% (95% CI 5.7 to 15.9) (met)

Result source: NCT04178967

tralokinumab · Adbry

Marketed by LEO Pharma and partners

Approved in Atopic Dermatitismonoclonal antibody
Reliable signal

NCT05958407 · Phase 3 · completed

The 235 participants were randomized 2:1 to tralokinumab or placebo and the initial 16-week comparison was double-blinded. The primary clinical endpoint—an Investigator’s Global Assessment score of 0 or 1 at Week 16—was met, occurring in 40.0% of the tralokinumab group versus 10.6% of the placebo group (p<.001).

Next expected readout: June 2030 · NCT07352566 (registry estimate)

Reported efficacy

Percentage of Participants With IGA-AHE Score of 0 (Clear) or 1 (Almost Clear) (At Week 16): Percentage of Participants With IGA-AHE Score of 0 (Clear) or 1 (Almost Clear) (At Week 16): Tralokinumab 40% (95% CI 31.3 to 49.4) vs Placebo 10.6% (95% CI 5 to 20.9) (met)

Result source: NCT05958407

Results for Atopic Dermatitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointlebrikizumabtralokinumab
EASI-7551.2% vs 13.4%+37.8 vs placebo250 mg Q2W · wk 16 · n 123NCT04760314
10 other results
  • 58.8% vs 16.2% Q2W · wk 16 · n 283 · Phase 3 · primary NCT04146363
  • 52.1% vs 18.1% Q2W · wk 16 · n 281 · Phase 3 · primary NCT04178967
  • 47.2% vs 13.4% 250 mg Q4W · wk 16 · n 81 · Phase 3 · primary NCT04760314
  • 69.5% vs 42.2% wk 16 · n 145 · Phase 3 · primary NCT04250337
  • 58% vs 32.7% 250 mg · wk 16 · n 125 · Phase 3 · secondary NCT04626297
  • 84.7% vs 72% 250 Q4W · wk 52 · n 53 · Phase 3 · secondary NCT04178967
  • 77.4% vs 72% 250 Q2W · wk 52 · n 51 · Phase 3 · secondary NCT04178967
  • 60.6% vs 24.3% 250 mg Q2W · wk 16 · n 75 · Phase 2 · secondary NCT03443024
  • 56.1% vs 24.3% 250 mg Q4W · wk 16 · n 80 · Phase 2 · secondary NCT03443024
  • 43.3% vs 24.3% 125 mg Q4W · wk 16 · n 73 · Phase 2 · secondary NCT03443024
25% vs 12.7%+12.3 vs placebo300 mg Q2W · wk 16 · n 601NCT03131648
8 other results
  • 33.2% vs 11.4% 300 mg Q2W · wk 16 · n 591 · Phase 3 · primary NCT03160885
  • 27.8% vs 6.4% 300 mg Q2W · wk 16 · n 97 · Phase 3 · primary NCT03526861
  • 28.6% vs 6.4% 150 mg Q2W · wk 16 · n 98 · Phase 3 · primary NCT03526861
  • 56% vs 35.7% Q2W+TCS · wk 16 · n 252 · Phase 3 · primary NCT03363854
  • 71.7% vs 56.6% wk 16 · n 53 · Phase 3 · primary NCT04587453
  • 64.2% vs 50.5% wk 16 · n 138 · Phase 3 · primary NCT03761537
  • 68.8% vs 55.3% wk 26 · n 138 · Phase 3 · secondary NCT03761537
  • 49.1% vs 36.1% wk 16 · n 106 · Phase 2 · secondary NCT03562377
IGA 0/1 with 2-point improvement33.4% vs 6.1%+27.3 vs placebo250 mg Q2W · wk 16 · n 123NCT04760314
5 other results
  • 29.1% vs 6.1% 250 mg Q4W · wk 16 · n 81 · Phase 3 · primary NCT04760314
  • 41.2% vs 22.1% wk 16 · n 145 · Phase 3 · primary NCT04250337
  • 44.6% vs 15.3% 250 mg Q2W · wk 16 · n 75 · Phase 2 · secondary NCT03443024
  • 33.7% vs 15.3% 250 mg Q4W · wk 16 · n 80 · Phase 2 · secondary NCT03443024
  • 26.6% vs 15.3% 125 mg Q4W · wk 16 · n 73 · Phase 2 · secondary NCT03443024
11.6% vs 11.8%−0.2 vs placebowk 12 · n 50NCT02347176
2 other results
  • 19.5% vs 11.8% wk 12 · n 51 · Phase 2 · primary NCT02347176
  • 26.7% vs 11.8% wk 12 · n 52 · Phase 2 · primary NCT02347176
EASI-9034.3% vs 9.8%+24.5 vs placebo250 mg Q2W · wk 16 · n 123NCT04760314
11 other results
  • 39.2% vs 18.9% 250 mg · wk 16 · n 125 · Phase 3 · secondary NCT04626297
  • 38.3% vs 9% Q2W · wk 16 · n 283 · Phase 3 · secondary NCT04146363
  • 30.7% vs 9.5% Q2W · wk 16 · n 281 · Phase 3 · secondary NCT04178967
  • 41.2% vs 21.7% wk 16 · n 145 · Phase 3 · secondary NCT04250337
  • 12.4% vs 1.6% Q2W · wk 4 · n 283 · Phase 3 · secondary NCT04146363
  • 6.3% vs 1.5% Q2W · wk 4 · n 281 · Phase 3 · secondary NCT04178967
  • 28.4% vs 9.8% 250 mg Q4W · wk 16 · n 81 · Phase 3 · secondary NCT04760314
  • 10.7% vs 7.2% wk 4 · n 145 · Phase 3 · secondary NCT04250337
  • 44% vs 11.4% 250 mg Q2W · wk 16 · n 75 · Phase 2 · secondary NCT03443024
  • 36.1% vs 11.4% 250 mg Q4W · wk 16 · n 80 · Phase 2 · secondary NCT03443024
  • 26.1% vs 11.4% 125 mg Q4W · wk 16 · n 73 · Phase 2 · secondary NCT03443024
14.5% vs 4.1%+10.4 vs placebo300 mg Q2W · wk 16 · n 601NCT03131648
5 other results
  • 18.3% vs 5.5% 300 mg Q2W · wk 16 · n 591 · Phase 3 · secondary NCT03160885
  • 17.5% vs 4.3% 300 mg Q2W · wk 16 · n 97 · Phase 3 · secondary NCT03526861
  • 19.4% vs 4.3% 150 mg Q2W · wk 16 · n 98 · Phase 3 · secondary NCT03526861
  • 32.9% vs 21.4% Q2W+TCS · wk 16 · n 252 · Phase 3 · secondary NCT03363854
  • 45.3% vs 30.2% wk 16 · n 53 · Phase 3 · secondary NCT04587453
EASI, % change-64.2% vs -25.3%−39 vs placebo250 mg Q2W · wk 16 · n 123NCT04760314
7 other results
  • -64.3% vs -26.0% Q2W · wk 16 · n 283 · Phase 3 · secondary NCT04146363
  • -61.5% vs -28.0% Q2W · wk 16 · n 281 · Phase 3 · secondary NCT04178967
  • -59.7% vs -25.3% 250 mg Q4W · wk 16 · n 81 · Phase 3 · secondary NCT04760314
  • -76.8% vs -53.1% wk 16 · n 145 · Phase 3 · secondary NCT04250337
  • -72.1% vs -41.1% 250 mg Q2W · wk 16 · n 75 · Phase 2 · primary NCT03443024
  • -69.2% vs -41.1% 250 mg Q4W · wk 16 · n 80 · Phase 2 · primary NCT03443024
  • -62.3% vs -41.1% 125 mg Q4W · wk 16 · n 73 · Phase 2 · primary NCT03443024
-77.8% vs -73.5%−4.3 vs placebowk 16 · n 53NCT04587453

EASI-75

lebrikizumab
51.2% vs 13.4%+37.8 vs placebo250 mg Q2W · wk 16 · n 123NCT04760314
10 other results
  • 58.8% vs 16.2% Q2W · wk 16 · n 283 · Phase 3 · primary NCT04146363
  • 52.1% vs 18.1% Q2W · wk 16 · n 281 · Phase 3 · primary NCT04178967
  • 47.2% vs 13.4% 250 mg Q4W · wk 16 · n 81 · Phase 3 · primary NCT04760314
  • 69.5% vs 42.2% wk 16 · n 145 · Phase 3 · primary NCT04250337
  • 58% vs 32.7% 250 mg · wk 16 · n 125 · Phase 3 · secondary NCT04626297
  • 84.7% vs 72% 250 Q4W · wk 52 · n 53 · Phase 3 · secondary NCT04178967
  • 77.4% vs 72% 250 Q2W · wk 52 · n 51 · Phase 3 · secondary NCT04178967
  • 60.6% vs 24.3% 250 mg Q2W · wk 16 · n 75 · Phase 2 · secondary NCT03443024
  • 56.1% vs 24.3% 250 mg Q4W · wk 16 · n 80 · Phase 2 · secondary NCT03443024
  • 43.3% vs 24.3% 125 mg Q4W · wk 16 · n 73 · Phase 2 · secondary NCT03443024
tralokinumab
25% vs 12.7%+12.3 vs placebo300 mg Q2W · wk 16 · n 601NCT03131648
8 other results
  • 33.2% vs 11.4% 300 mg Q2W · wk 16 · n 591 · Phase 3 · primary NCT03160885
  • 27.8% vs 6.4% 300 mg Q2W · wk 16 · n 97 · Phase 3 · primary NCT03526861
  • 28.6% vs 6.4% 150 mg Q2W · wk 16 · n 98 · Phase 3 · primary NCT03526861
  • 56% vs 35.7% Q2W+TCS · wk 16 · n 252 · Phase 3 · primary NCT03363854
  • 71.7% vs 56.6% wk 16 · n 53 · Phase 3 · primary NCT04587453
  • 64.2% vs 50.5% wk 16 · n 138 · Phase 3 · primary NCT03761537
  • 68.8% vs 55.3% wk 26 · n 138 · Phase 3 · secondary NCT03761537
  • 49.1% vs 36.1% wk 16 · n 106 · Phase 2 · secondary NCT03562377

IGA 0/1 with 2-point improvement

lebrikizumab
33.4% vs 6.1%+27.3 vs placebo250 mg Q2W · wk 16 · n 123NCT04760314
5 other results
  • 29.1% vs 6.1% 250 mg Q4W · wk 16 · n 81 · Phase 3 · primary NCT04760314
  • 41.2% vs 22.1% wk 16 · n 145 · Phase 3 · primary NCT04250337
  • 44.6% vs 15.3% 250 mg Q2W · wk 16 · n 75 · Phase 2 · secondary NCT03443024
  • 33.7% vs 15.3% 250 mg Q4W · wk 16 · n 80 · Phase 2 · secondary NCT03443024
  • 26.6% vs 15.3% 125 mg Q4W · wk 16 · n 73 · Phase 2 · secondary NCT03443024
tralokinumab
11.6% vs 11.8%−0.2 vs placebowk 12 · n 50NCT02347176
2 other results
  • 19.5% vs 11.8% wk 12 · n 51 · Phase 2 · primary NCT02347176
  • 26.7% vs 11.8% wk 12 · n 52 · Phase 2 · primary NCT02347176

EASI-90

lebrikizumab
34.3% vs 9.8%+24.5 vs placebo250 mg Q2W · wk 16 · n 123NCT04760314
11 other results
  • 39.2% vs 18.9% 250 mg · wk 16 · n 125 · Phase 3 · secondary NCT04626297
  • 38.3% vs 9% Q2W · wk 16 · n 283 · Phase 3 · secondary NCT04146363
  • 30.7% vs 9.5% Q2W · wk 16 · n 281 · Phase 3 · secondary NCT04178967
  • 41.2% vs 21.7% wk 16 · n 145 · Phase 3 · secondary NCT04250337
  • 12.4% vs 1.6% Q2W · wk 4 · n 283 · Phase 3 · secondary NCT04146363
  • 6.3% vs 1.5% Q2W · wk 4 · n 281 · Phase 3 · secondary NCT04178967
  • 28.4% vs 9.8% 250 mg Q4W · wk 16 · n 81 · Phase 3 · secondary NCT04760314
  • 10.7% vs 7.2% wk 4 · n 145 · Phase 3 · secondary NCT04250337
  • 44% vs 11.4% 250 mg Q2W · wk 16 · n 75 · Phase 2 · secondary NCT03443024
  • 36.1% vs 11.4% 250 mg Q4W · wk 16 · n 80 · Phase 2 · secondary NCT03443024
  • 26.1% vs 11.4% 125 mg Q4W · wk 16 · n 73 · Phase 2 · secondary NCT03443024
tralokinumab
14.5% vs 4.1%+10.4 vs placebo300 mg Q2W · wk 16 · n 601NCT03131648
5 other results
  • 18.3% vs 5.5% 300 mg Q2W · wk 16 · n 591 · Phase 3 · secondary NCT03160885
  • 17.5% vs 4.3% 300 mg Q2W · wk 16 · n 97 · Phase 3 · secondary NCT03526861
  • 19.4% vs 4.3% 150 mg Q2W · wk 16 · n 98 · Phase 3 · secondary NCT03526861
  • 32.9% vs 21.4% Q2W+TCS · wk 16 · n 252 · Phase 3 · secondary NCT03363854
  • 45.3% vs 30.2% wk 16 · n 53 · Phase 3 · secondary NCT04587453

EASI, % change

lebrikizumab
-64.2% vs -25.3%−39 vs placebo250 mg Q2W · wk 16 · n 123NCT04760314
7 other results
  • -64.3% vs -26.0% Q2W · wk 16 · n 283 · Phase 3 · secondary NCT04146363
  • -61.5% vs -28.0% Q2W · wk 16 · n 281 · Phase 3 · secondary NCT04178967
  • -59.7% vs -25.3% 250 mg Q4W · wk 16 · n 81 · Phase 3 · secondary NCT04760314
  • -76.8% vs -53.1% wk 16 · n 145 · Phase 3 · secondary NCT04250337
  • -72.1% vs -41.1% 250 mg Q2W · wk 16 · n 75 · Phase 2 · primary NCT03443024
  • -69.2% vs -41.1% 250 mg Q4W · wk 16 · n 80 · Phase 2 · primary NCT03443024
  • -62.3% vs -41.1% 125 mg Q4W · wk 16 · n 73 · Phase 2 · primary NCT03443024
tralokinumab
-77.8% vs -73.5%−4.3 vs placebowk 16 · n 53NCT04587453
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
10 other shared endpoints and safety

Coverage. lebrikizumab: 14 of 14 rows · tralokinumab: 14 of 14 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metriclebrikizumab
Rows use multiple source trials
tralokinumab
Rows use multiple source trials
CDLQI
absolute change · score
-8 vs -1 placebo score @ 16wkQ2Wa,b
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
2 other source trials
-7.6 vs -3.4 placebo score @ 16wkQ2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-9.33 vs -4.71 placebo score @ 16wk
NCT04250337 · Phase 3 · combination
-6.7 vs -4.1 placebo score @ 16wk300 mg Q2Wc,a,b
NCT03526861 · Phase 3
show 1 more dose
-6.1 vs -4.1 placebo score @ 16wk150 mg Q2W
NCT03526861 · Phase 3
DLQI
absolute change · score
-8.7 vs -2.9 placebo score @ 16wkQ2Wa,b
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
2 other source trials
-7.3 vs -2.4 placebo score @ 16wkQ2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-9.79 vs -6.46 placebo score @ 16wk
NCT04250337 · Phase 3 · combination
-7.1 vs -5 placebo score @ 16wk300 mg Q2Wa,b
NCT03131648 · Phase 3
4 other source trials
-8.8 vs -4.9 placebo score @ 16wk300 mg Q2W
NCT03160885 · Phase 3
-11.7 vs -8.8 placebo score @ 16wkQ2W+TCS
NCT03363854 · Phase 3 · combination
-10 vs -8.8 placebo score @ 16wk
NCT04587453 · Phase 3 · registry result, not featured evidence · combination
-11.2 vs -9.6 placebo score @ 16wk
NCT03761537 · Phase 3 · registry result, not featured evidence · combination
DLQI ≥4
responder rate · % of participants
77.4% (n=105) vs 58.7% (n=48) placebo @ 16wka,b
NCT04250337 · Phase 3 · combination
44.6% (n=578) vs 31.6% (n=190) placebo @ 16wk*300 mg Q2Wa,b
NCT03131648 · Phase 3 · converted to % from 258 Participants as posted
EASI-50
responder rate · % of participants
81% (n=75) vs 45.8% (n=52) placebo @ 16wk250 mg Q2Wc,d,a,b
NCT03443024 · Phase 2 · registry result, not featured evidence
show 2 more doses
77% (n=80) vs 45.8% (n=52) placebo @ 16wk250 mg Q4W
NCT03443024 · Phase 2 · registry result, not featured evidence
66.4% (n=73) vs 45.8% (n=52) placebo @ 16wk125 mg Q4W
NCT03443024 · Phase 2 · registry result, not featured evidence
41.6% (n=601) vs 21.3% (n=197) placebo @ 16wk*300 mg Q2Wd,a,b
NCT03131648 · Phase 3 · converted to % from 250 Participants as posted
5 other source trials
49.9% (n=591) vs 20.4% (n=201) placebo @ 16wk*300 mg Q2W
NCT03160885 · Phase 3 · converted to % from 295 Participants as posted
79.4% (n=252) vs 57.9% (n=126) placebo @ 16wk*Q2W+TCS
NCT03363854 · Phase 3 · combination · converted to % from 200 Participants as posted
45.9% (n=98) vs 13.8% (n=94) placebo @ 16wk*150 mg Q2W
NCT03526861 · Phase 3 · converted to % from 45 Participants as posted
51.5% (n=97) vs 13.8% (n=94) placebo @ 16wk*300 mg Q2W
NCT03526861 · Phase 3 · converted to % from 50 Participants as posted
84.9% (n=53) vs 79.2% (n=53) placebo @ 16wk*
NCT04587453 · Phase 3 · registry result, not featured evidence · combination · converted to % from 45 Participants as posted
EASI-75
responder rate · % of participants
No placebo or comparator arm
81.9% (n=206) @ 52wk250 mga,b
NCT04250350 · Phase 3 · registry result, not featured evidence
53.8% (n=13) @ 52wk*300 mg Q4Wc,a,b
NCT03526861 · Phase 3 · converted to % from 7 Participants as posted
show 3 more doses
44.4% (n=9) @ 52wk*300 mg Q2W
NCT03526861 · Phase 3 · converted to % from 4 Participants as posted
63.6% (n=11) @ 52wk*150 mg Q2W
NCT03526861 · Phase 3 · converted to % from 7 Participants as posted
50% (n=14) @ 52wk*150 mg Q4W
NCT03526861 · Phase 3 · converted to % from 7 Participants as posted
EASI-75 Sustained
responder rate · % of participants
79.2% (n=61) vs 61.3% (n=30) placebo @ 52wk250 Q2Wc,a,b
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 1 more dose
79.2% (n=62) vs 61.3% (n=30) placebo @ 52wk250 Q4W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
49.1% (n=57) vs 33.3% (n=30) placebo @ 52wk*300 mg Q4Wc,a,b
NCT03131648 · Phase 3 · converted to % from 28 Participants as posted
show 1 more dose
59.6% (n=47) vs 33.3% (n=30) placebo @ 52wk*300 mg Q2W
NCT03131648 · Phase 3 · converted to % from 28 Participants as posted
IGA 0 1 Sustained
responder rate · % of participants
75.8% (n=45) vs 46.5% (n=22) placebo @ 52wk250 Q2Wc,a,b
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 1 more dose
74.2% (n=45) vs 46.5% (n=22) placebo @ 52wk250 Q4W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
38.9% (n=36) vs 47.4% (n=19) placebo @ 52wk*300 mg Q4Wc,a,b
NCT03131648 · Phase 3 · converted to % from 14 Participants as posted
show 1 more dose
51.3% (n=39) vs 47.4% (n=19) placebo @ 52wk*300 mg Q2W
NCT03131648 · Phase 3 · converted to % from 20 Participants as posted
IGA 0/1
responder rate · % of participants
43.1% (n=283) vs 12.7% (n=141) placebo @ 16wkQ2Wc,a,b
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 1 more dose
42.2% (n=246) vs 11.3% (n=123) placebo @ 16wkQ2W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
15.8% (n=601) vs 7.1% (n=197) placebo @ 16wk*300 mg Q2Wa,b
NCT03131648 · Phase 3 · converted to % from 95 Participants as posted
7 other source trials
22.2% (n=591) vs 10.9% (n=201) placebo @ 16wk*300 mg Q2W
NCT03160885 · Phase 3 · converted to % from 131 Participants as posted
38.9% (n=252) vs 26.2% (n=126) placebo @ 16wk*Q2W+TCS
NCT03363854 · Phase 3 · combination · converted to % from 98 Participants as posted
21.4% (n=98) vs 4.3% (n=94) placebo @ 16wk*150 mg Q2W
NCT03526861 · Phase 3 · converted to % from 21 Participants as posted
17.5% (n=97) vs 4.3% (n=94) placebo @ 16wk*300 mg Q2W
NCT03526861 · Phase 3 · converted to % from 17 Participants as posted
32.1% (n=53) vs 26.4% (n=53) placebo @ 16wk*
NCT04587453 · Phase 3 · registry result, not featured evidence · combination · converted to % from 17 Participants as posted
40.9% (n=138) vs 26% (n=137) placebo @ 16wk
NCT03761537 · Phase 3 · registry result, not featured evidence · combination
31.1% (n=106) vs 19.4% (n=108) placebo @ 16wk*
NCT03562377 · Phase 2 · registry result, not featured evidence · converted to % from 33 Participants as posted
IGA 0/1
responder rate · % of participants
No placebo or comparator arm
62.6% (n=206) @ 52wk250 mga,b
NCT04250350 · Phase 3 · registry result, not featured evidence
87.5% (n=8) @ 52wk*300 mg Q4Wc,a,b
NCT03526861 · Phase 3 · converted to % from 7 Participants as posted
show 3 more doses
37.5% (n=8) @ 52wk*300 mg Q2W
NCT03526861 · Phase 3 · converted to % from 3 Participants as posted
66.7% (n=9) @ 52wk*150 mg Q2W
NCT03526861 · Phase 3 · converted to % from 6 Participants as posted
60% (n=10) @ 52wk*150 mg Q4W
NCT03526861 · Phase 3 · converted to % from 6 Participants as posted
POEM
absolute change · score
-11.3 vs -3.9 placebo score @ 16wkQ2Wa,b
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
2 other source trials
-9.5 vs -3.5 placebo score @ 16wkQ2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-10.23 vs -6.24 placebo score @ 16wk
NCT04250337 · Phase 3 · combination
-8.4 vs -2.4 placebo score @ 16wk300 mg Q2Wc,a,b
NCT03526861 · Phase 3
show 1 more dose
-7.8 vs -2.4 placebo score @ 16wk150 mg Q2W
NCT03526861 · Phase 3
Dropout rate
—250mg Q2We
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 54 more results
—Q2W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—Q2W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—Escape Arm Week 24 to 48 - Mainten
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—Q2W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—Q4W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—Q2W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—Q4W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—250 Q2W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—250 Q4W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—250mg Q2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—Q2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—Q2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—Escape Arm Week 24 to 48 - Mainten
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—Q2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—Q4W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—Q2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—Q4W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—250 Q2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—250 Q4W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
7.2%
NCT04250337 · Phase 3 · combination
6.5%
NCT05990725 · Phase 3 · registry result, not featured evidence
—Q4W
NCT04392154 · Phase 3 · registry result, not featured evidence
—Q8W
NCT04392154 · Phase 3 · registry result, not featured evidence
33.3%Q2W
NCT04392154 · Phase 3 · registry result, not featured evidence
27%Q4W
NCT04392154 · Phase 3 · registry result, not featured evidence
14.4%250 mg Q2W
NCT05372419 · Phase 3 · registry result, not featured evidence
—250 mg Q2W
NCT05372419 · Phase 3 · registry result, not featured evidence
—250 mg Q2W then 250 mg Q4W
NCT05372419 · Phase 3 · registry result, not featured evidence
—250 mg Q2W
NCT05372419 · Phase 3 · registry result, not featured evidence
—250 mg Q2W then 250 mg Q4W
NCT05372419 · Phase 3 · registry result, not featured evidence
31.4%250 mg Q2W
NCT05369403 · Phase 3 · registry result, not featured evidence
—250 mg Q2W
NCT05369403 · Phase 3 · registry result, not featured evidence
—250 mg Q2W then 250 mg Q4W
NCT05369403 · Phase 3 · registry result, not featured evidence
—250 mg Q2W
NCT05369403 · Phase 3 · registry result, not featured evidence
—250 mg Q2W then Q4W
NCT05369403 · Phase 3 · registry result, not featured evidence
0%Lebrikizumab Pen
NCT06444165 · Phase 3 · registry result, not featured evidence
—Lebrikuzimab Pen
NCT06444165 · Phase 3 · registry result, not featured evidence
3.6%Double-blind Induction Period: Leb
NCT05149313 · Phase 3 · registry result, not featured evidence · combination
—Open-label Maintenance Period: Leb
NCT05149313 · Phase 3 · registry result, not featured evidence
—250 mg Q2W
NCT04760314 · Phase 3 · registry result, not featured evidence
—250mg Q2W
NCT04760314 · Phase 3 · registry result, not featured evidence
—250mg Q2W
NCT04760314 · Phase 3 · registry result, not featured evidence
2.4%250mg Q2W
NCT04760314 · Phase 3 · registry result, not featured evidence
1.2%250mg Q4W
NCT04760314 · Phase 3 · registry result, not featured evidence
—250 Q2W
NCT04760314 · Phase 3 · registry result, not featured evidence
—Q4W
NCT04760314 · Phase 3 · registry result, not featured evidence
—Q2W
NCT04760314 · Phase 3 · registry result, not featured evidence
—Q4W
NCT04760314 · Phase 3 · registry result, not featured evidence
11%250 mg
NCT04626297 · Phase 3 · registry result, not featured evidence
16.5%250 mg
NCT04250350 · Phase 3 · registry result, not featured evidence
—250 mg
NCT04250350 · Phase 3 · registry result, not featured evidence
—250 mg Q2W
NCT03443024 · Phase 2 · registry result, not featured evidence
38.8%250 mg Q4W
NCT03443024 · Phase 2 · registry result, not featured evidence
—125 mg Q4W
NCT03443024 · Phase 2 · registry result, not featured evidence
4.5%Tralokinumabf
NCT05958407 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 43 more results
—Tralokinumab DB
NCT05958407 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—Tralokinumab OL
NCT05958407 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—Q2W
NCT03131648 · Phase 3
—Q2W
NCT03131648 · Phase 3
—Q4W
NCT03131648 · Phase 3
—Q2W + optional TCS
NCT03131648 · Phase 3 · combination
5.9%300 mg Q2W
NCT03160885 · Phase 3
—Q2W
NCT03160885 · Phase 3
—Q2W
NCT03160885 · Phase 3
—Q4W
NCT03160885 · Phase 3
—Q2W + Optional TCS
NCT03160885 · Phase 3 · combination
—Q2W+TCS
NCT03363854 · Phase 3 · combination
—Q2W+TCS
NCT03363854 · Phase 3 · combination
—Q2W+TCS
NCT03363854 · Phase 3 · combination
—Q4W+TCS
NCT03363854 · Phase 3 · combination
—Q2W+TCS
NCT03363854 · Phase 3 · combination
7.1%Q2W+TCS
NCT03363854 · Phase 3 · combination
—Q2W+TCS
NCT03363854 · Phase 3 · combination
—Q4W+TCS
NCT03363854 · Phase 3 · combination
—300 mg Q4W
NCT03526861 · Phase 3
6.9%300 mg Q2W
NCT03526861 · Phase 3
—300 mg Q2W
NCT03526861 · Phase 3
7%150 mg Q2W
NCT03526861 · Phase 3
—150 mg Q2W
NCT03526861 · Phase 3
—150 mg Q4W
NCT03526861 · Phase 3
—300 mg Q2W
NCT03526861 · Phase 3 · combination
—150 Q2W
NCT03526861 · Phase 3
—300 Q2W
NCT03526861 · Phase 3
—150 Q2W
NCT03526861 · Phase 3
—150 Q4W
NCT03526861 · Phase 3
—300 Q2W
NCT03526861 · Phase 3
—300 Q4W
NCT03526861 · Phase 3
—300 Q2W
NCT03526861 · Phase 3 · combination
31.6%
NCT03587805 · Phase 3 · registry result, not featured evidence
14%Tralokinumab Subcutaneous Dosing b
NCT05194540 · Phase 3 · registry result, not featured evidence
—Tralokinumab+TCS Initial Treatment
NCT05194540 · Phase 3 · registry result, not featured evidence · combination
0%
NCT04587453 · Phase 3 · registry result, not featured evidence · combination
—Safety Follow-up Period: Tralokinu
NCT03761537 · Phase 3 · registry result, not featured evidence · combination
—Treatment Period: Tralokinumab+TCS
NCT03761537 · Phase 3 · registry result, not featured evidence · combination
6.5%
NCT03562377 · Phase 2 · registry result, not featured evidence
20%Tralokinumab Dose 1
NCT02347176 · Phase 2 · registry result, not featured evidence
15.7%Tralokinumab Dose 2
NCT02347176 · Phase 2 · registry result, not featured evidence
7.7%Tralokinumab Dose 3
NCT02347176 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—250mg Q2We
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 54 more results
—Q2W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—Q2W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—Escape Arm Week 24 to 48 - Mainten
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—Q2W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—Q4W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—Q2W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—Q4W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—250 Q2W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—250 Q4W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—250mg Q2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—Q2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—Q2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—Escape Arm Week 24 to 48 - Mainten
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—Q2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—Q4W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—Q2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—Q4W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—250 Q2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—250 Q4W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
2%
NCT04250337 · Phase 3 · combination
1.9%
NCT05990725 · Phase 3 · registry result, not featured evidence
—Q4W
NCT04392154 · Phase 3 · registry result, not featured evidence
—Q8W
NCT04392154 · Phase 3 · registry result, not featured evidence
4.5%Q2W
NCT04392154 · Phase 3 · registry result, not featured evidence
2.1%Q4W
NCT04392154 · Phase 3 · registry result, not featured evidence
—250 mg Q2W
NCT05372419 · Phase 3 · registry result, not featured evidence
—250 mg Q2W
NCT05372419 · Phase 3 · registry result, not featured evidence
—250 mg Q2W then 250 mg Q4W
NCT05372419 · Phase 3 · registry result, not featured evidence
—250 mg Q2W
NCT05372419 · Phase 3 · registry result, not featured evidence
—250 mg Q2W then 250 mg Q4W
NCT05372419 · Phase 3 · registry result, not featured evidence
5.8%250 mg Q2W
NCT05369403 · Phase 3 · registry result, not featured evidence
—250 mg Q2W
NCT05369403 · Phase 3 · registry result, not featured evidence
—250 mg Q2W then 250 mg Q4W
NCT05369403 · Phase 3 · registry result, not featured evidence
—250 mg Q2W
NCT05369403 · Phase 3 · registry result, not featured evidence
—250 mg Q2W then Q4W
NCT05369403 · Phase 3 · registry result, not featured evidence
—Lebrikizumab Pen
NCT06444165 · Phase 3 · registry result, not featured evidence
—Lebrikuzimab Pen
NCT06444165 · Phase 3 · registry result, not featured evidence
0.9%Double-blind Induction Period: Leb
NCT05149313 · Phase 3 · registry result, not featured evidence · combination
—Open-label Maintenance Period: Leb
NCT05149313 · Phase 3 · registry result, not featured evidence
—250 mg Q2W
NCT04760314 · Phase 3 · registry result, not featured evidence
—250mg Q2W
NCT04760314 · Phase 3 · registry result, not featured evidence
—250mg Q2W
NCT04760314 · Phase 3 · registry result, not featured evidence
1.6%250mg Q2W
NCT04760314 · Phase 3 · registry result, not featured evidence
0%250mg Q4W
NCT04760314 · Phase 3 · registry result, not featured evidence
—250 Q2W
NCT04760314 · Phase 3 · registry result, not featured evidence
—Q4W
NCT04760314 · Phase 3 · registry result, not featured evidence
—Q2W
NCT04760314 · Phase 3 · registry result, not featured evidence
—Q4W
NCT04760314 · Phase 3 · registry result, not featured evidence
2.4%250 mg
NCT04626297 · Phase 3 · registry result, not featured evidence
2.4%250 mg
NCT04250350 · Phase 3 · registry result, not featured evidence
—250 mg
NCT04250350 · Phase 3 · registry result, not featured evidence
—250 mg Q2W
NCT03443024 · Phase 2 · registry result, not featured evidence
5%250 mg Q4W
NCT03443024 · Phase 2 · registry result, not featured evidence
—125 mg Q4W
NCT03443024 · Phase 2 · registry result, not featured evidence
0.6%Tralokinumabf
NCT05958407 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 43 more results
—Tralokinumab DB
NCT05958407 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—Tralokinumab OL
NCT05958407 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—Q2W
NCT03131648 · Phase 3
—Q2W
NCT03131648 · Phase 3
—Q4W
NCT03131648 · Phase 3
—Q2W + optional TCS
NCT03131648 · Phase 3 · combination
—300 mg Q2W
NCT03160885 · Phase 3
—Q2W
NCT03160885 · Phase 3
—Q2W
NCT03160885 · Phase 3
—Q4W
NCT03160885 · Phase 3
—Q2W + Optional TCS
NCT03160885 · Phase 3 · combination
—Q2W+TCS
NCT03363854 · Phase 3 · combination
—Q2W+TCS
NCT03363854 · Phase 3 · combination
—Q2W+TCS
NCT03363854 · Phase 3 · combination
—Q4W+TCS
NCT03363854 · Phase 3 · combination
—Q2W+TCS
NCT03363854 · Phase 3 · combination
—Q2W+TCS
NCT03363854 · Phase 3 · combination
—Q2W+TCS
NCT03363854 · Phase 3 · combination
—Q4W+TCS
NCT03363854 · Phase 3 · combination
—300 mg Q4W
NCT03526861 · Phase 3
—300 mg Q2W
NCT03526861 · Phase 3
—300 mg Q2W
NCT03526861 · Phase 3
—150 mg Q2W
NCT03526861 · Phase 3
—150 mg Q2W
NCT03526861 · Phase 3
—150 mg Q4W
NCT03526861 · Phase 3
—300 mg Q2W
NCT03526861 · Phase 3 · combination
—150 Q2W
NCT03526861 · Phase 3
—300 Q2W
NCT03526861 · Phase 3
—150 Q2W
NCT03526861 · Phase 3
—150 Q4W
NCT03526861 · Phase 3
—300 Q2W
NCT03526861 · Phase 3
—300 Q4W
NCT03526861 · Phase 3
—300 Q2W
NCT03526861 · Phase 3 · combination
4.3%
NCT03587805 · Phase 3 · registry result, not featured evidence
—Tralokinumab Subcutaneous Dosing b
NCT05194540 · Phase 3 · registry result, not featured evidence
—Tralokinumab+TCS Initial Treatment
NCT05194540 · Phase 3 · registry result, not featured evidence · combination
—
NCT04587453 · Phase 3 · registry result, not featured evidence · combination
—Safety Follow-up Period: Tralokinu
NCT03761537 · Phase 3 · registry result, not featured evidence · combination
—Treatment Period: Tralokinumab+TCS
NCT03761537 · Phase 3 · registry result, not featured evidence · combination
—
NCT03562377 · Phase 2 · registry result, not featured evidence
—Tralokinumab Dose 1
NCT02347176 · Phase 2 · registry result, not featured evidence
—Tralokinumab Dose 2
NCT02347176 · Phase 2 · registry result, not featured evidence
—Tralokinumab Dose 3
NCT02347176 · Phase 2 · registry result, not featured evidence
Serious AEs
2.1%250mg Q2We
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 54 more results
3.8%Q2W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
1%Q2W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0%Escape Arm Week 24 to 48 - Mainten
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0%Q2W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
3.2%Q4W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0%Q2W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0%Q4W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—250 Q2W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—250 Q4W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0.7%250mg Q2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
4%Q2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0.9%Q2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0%Escape Arm Week 24 to 48 - Mainten
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
3.4%Q2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0%Q4W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0%Q2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
22.2%Q4W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—250 Q2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—250 Q4W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
1.3%
NCT04250337 · Phase 3 · combination
2.7%
NCT05990725 · Phase 3 · registry result, not featured evidence
0%Q4W
NCT04392154 · Phase 3 · registry result, not featured evidence
0%Q8W
NCT04392154 · Phase 3 · registry result, not featured evidence
4.4%Q2W
NCT04392154 · Phase 3 · registry result, not featured evidence
3.5%Q4W
NCT04392154 · Phase 3 · registry result, not featured evidence
0%250 mg Q2W
NCT05372419 · Phase 3 · registry result, not featured evidence
—250 mg Q2W
NCT05372419 · Phase 3 · registry result, not featured evidence
—250 mg Q2W then 250 mg Q4W
NCT05372419 · Phase 3 · registry result, not featured evidence
0%250 mg Q2W
NCT05372419 · Phase 3 · registry result, not featured evidence
1.8%250 mg Q2W then 250 mg Q4W
NCT05372419 · Phase 3 · registry result, not featured evidence
1.2%250 mg Q2W
NCT05369403 · Phase 3 · registry result, not featured evidence
—250 mg Q2W
NCT05369403 · Phase 3 · registry result, not featured evidence
—250 mg Q2W then 250 mg Q4W
NCT05369403 · Phase 3 · registry result, not featured evidence
0%250 mg Q2W
NCT05369403 · Phase 3 · registry result, not featured evidence
2.4%250 mg Q2W then Q4W
NCT05369403 · Phase 3 · registry result, not featured evidence
—Lebrikizumab Pen
NCT06444165 · Phase 3 · registry result, not featured evidence
0%Lebrikuzimab Pen
NCT06444165 · Phase 3 · registry result, not featured evidence
1.4%Double-blind Induction Period: Leb
NCT05149313 · Phase 3 · registry result, not featured evidence · combination
5.7%Open-label Maintenance Period: Leb
NCT05149313 · Phase 3 · registry result, not featured evidence
1.4%250 mg Q2W
NCT04760314 · Phase 3 · registry result, not featured evidence
1.8%250mg Q2W
NCT04760314 · Phase 3 · registry result, not featured evidence
4.8%250mg Q2W
NCT04760314 · Phase 3 · registry result, not featured evidence
0.8%250mg Q2W
NCT04760314 · Phase 3 · registry result, not featured evidence
0%250mg Q4W
NCT04760314 · Phase 3 · registry result, not featured evidence
12.5%250 Q2W
NCT04760314 · Phase 3 · registry result, not featured evidence
0%Q4W
NCT04760314 · Phase 3 · registry result, not featured evidence
3.1%Q2W
NCT04760314 · Phase 3 · registry result, not featured evidence
2.6%Q4W
NCT04760314 · Phase 3 · registry result, not featured evidence
0.8%250 mg
NCT04626297 · Phase 3 · registry result, not featured evidence
—250 mg
NCT04250350 · Phase 3 · registry result, not featured evidence
2.4%250 mg
NCT04250350 · Phase 3 · registry result, not featured evidence
2.7%250 mg Q2W
NCT03443024 · Phase 2 · registry result, not featured evidence
0%250 mg Q4W
NCT03443024 · Phase 2 · registry result, not featured evidence
2.7%125 mg Q4W
NCT03443024 · Phase 2 · registry result, not featured evidence
—Tralokinumabf
NCT05958407 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 43 more results
1.9%Tralokinumab DB
NCT05958407 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
1.9%Tralokinumab OL
NCT05958407 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
3.8%Q2W
NCT03131648 · Phase 3
1.5%Q2W
NCT03131648 · Phase 3
3.9%Q4W
NCT03131648 · Phase 3
4.8%Q2W + optional TCS
NCT03131648 · Phase 3 · combination
—300 mg Q2W
NCT03160885 · Phase 3
1.7%Q2W
NCT03160885 · Phase 3
0%Q2W
NCT03160885 · Phase 3
3.4%Q4W
NCT03160885 · Phase 3
2.9%Q2W + Optional TCS
NCT03160885 · Phase 3 · combination
0%Q2W+TCS
NCT03363854 · Phase 3 · combination
2.1%Q2W+TCS
NCT03363854 · Phase 3 · combination
4.3%Q2W+TCS
NCT03363854 · Phase 3 · combination
0%Q4W+TCS
NCT03363854 · Phase 3 · combination
0.8%Q2W+TCS
NCT03363854 · Phase 3 · combination
—Q2W+TCS
NCT03363854 · Phase 3 · combination
—Q2W+TCS
NCT03363854 · Phase 3 · combination
—Q4W+TCS
NCT03363854 · Phase 3 · combination
—300 mg Q4W
NCT03526861 · Phase 3
—300 mg Q2W
NCT03526861 · Phase 3
—300 mg Q2W
NCT03526861 · Phase 3
—150 mg Q2W
NCT03526861 · Phase 3
—150 mg Q2W
NCT03526861 · Phase 3
—150 mg Q4W
NCT03526861 · Phase 3
—300 mg Q2W
NCT03526861 · Phase 3 · combination
3.1%150 Q2W
NCT03526861 · Phase 3
1%300 Q2W
NCT03526861 · Phase 3
0%150 Q2W
NCT03526861 · Phase 3
0%150 Q4W
NCT03526861 · Phase 3
0%300 Q2W
NCT03526861 · Phase 3
0%300 Q4W
NCT03526861 · Phase 3
3%300 Q2W
NCT03526861 · Phase 3 · combination
9%
NCT03587805 · Phase 3 · registry result, not featured evidence
—Tralokinumab Subcutaneous Dosing b
NCT05194540 · Phase 3 · registry result, not featured evidence
0%Tralokinumab+TCS Initial Treatment
NCT05194540 · Phase 3 · registry result, not featured evidence · combination
—
NCT04587453 · Phase 3 · registry result, not featured evidence · combination
0%Safety Follow-up Period: Tralokinu
NCT03761537 · Phase 3 · registry result, not featured evidence · combination
0.7%Treatment Period: Tralokinumab+TCS
NCT03761537 · Phase 3 · registry result, not featured evidence · combination
2.8%
NCT03562377 · Phase 2 · registry result, not featured evidence
6%Tralokinumab Dose 1
NCT02347176 · Phase 2 · registry result, not featured evidence
3.9%Tralokinumab Dose 2
NCT02347176 · Phase 2 · registry result, not featured evidence
0%Tralokinumab Dose 3
NCT02347176 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
250mg Q2We
conjunctivitis 7.4% (placebo 2.8%)
dermatitis atopic 5.7% (placebo 21.3%)
nasopharyngitis 3.9% (placebo 2.8%)
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 43 more results
Q2W
conjunctivitis 4.7% (placebo 2.8%)
conjunctivitis allergic 4.7% (placebo 0.7%)
asthma 3.8% (placebo 0.7%)
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
Q2W
conjunctivitis 9.4% (placebo 2.8%)
conjunctivitis allergic 6.3% (placebo 0.7%)
dermatitis atopic 6.3% (placebo 21.3%)
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
bursitis 5.6% (placebo 0.7%)
carpal tunnel syndrome 5.6% (placebo 0%)
conjunctivitis 5.6% (placebo 2.8%)
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
Q2W
covid-19 3.2% (placebo 2.1%)
dermatitis atopic 3.2% (placebo 21.3%)
hypertension 3.2% (placebo 0.7%)
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
Q4W
covid-19 12.7% (placebo 2.1%)
nasopharyngitis 9.5% (placebo 2.8%)
dermatitis atopic 6.3% (placebo 21.3%)
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
Q2W
abscess limb 10% (placebo 0%)
chest wall abscess 10% (placebo 0%)
nasopharyngitis 10% (placebo 2.8%)
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
Q4W
covid-19 10% (placebo 2.1%)
nasopharyngitis 10% (placebo 2.8%)
oral herpes 10% (placebo 3.5%)
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
250mg Q2W
dermatitis atopic 9.2% (placebo 25.5%)
conjunctivitis 7.1% (placebo 2%)
headache 5.1% (placebo 5.4%)
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
Q2W
nasopharyngitis 8% (placebo 2%)
dermatitis atopic 4.8% (placebo 25.5%)
conjunctivitis 2.4% (placebo 2%)
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
Q2W
conjunctivitis allergic 11.1% (placebo 1.3%)
covid-19 5.6% (placebo 1.3%)
nasopharyngitis 5.6% (placebo 2%)
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
asthma 18.2% (placebo 0%)
dermatitis atopic 18.2% (placebo 25.5%)
herpes dermatitis 9.1% (placebo 1.3%)
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
Q2W
vaccination complication 6.8% (placebo 0%)
dermatitis atopic 5.1% (placebo 25.5%)
folliculitis 5.1% (placebo 2%)
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
Q4W
conjunctivitis 8.5% (placebo 2%)
conjunctivitis allergic 6.8% (placebo 1.3%)
covid-19 5.1% (placebo 1.3%)
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
Q2W
hypercholesterolaemia 18.2% (placebo 0.7%)
nasopharyngitis 18.2% (placebo 2%)
acne 9.1% (placebo 2%)
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
Q4W
arthralgia 11.1% (placebo 0.7%)
blood lactate dehydrogenase increased 11.1% (placebo 0%)
blood uric acid increased 11.1% (placebo 0%)
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
conjunctivitis 4.6% (placebo 0%)
headache 4.6% (placebo 1.3%)
hypertension 2.6% (placebo 1.3%)
NCT04250337 · Phase 3 · combination
nasopharyngitis 25.4%
conjunctivitis 17.7%
dermatitis atopic 11.5%
NCT05990725 · Phase 3 · registry result, not featured evidence
Q4W
nasopharyngitis 3.8%
acne 1.9%
attention deficit hyperactivity disorder 1.9%
NCT04392154 · Phase 3 · registry result, not featured evidence
Q8W
accessory navicular syndrome 2%
alanine aminotransferase increased 2%
arthralgia 2%
NCT04392154 · Phase 3 · registry result, not featured evidence
Q2W
covid-19 15.7%
nasopharyngitis 11.4%
dermatitis atopic 6.9%
NCT04392154 · Phase 3 · registry result, not featured evidence
Q4W
covid-19 18.4%
nasopharyngitis 9.2%
dermatitis atopic 6.4%
NCT04392154 · Phase 3 · registry result, not featured evidence
250 mg Q2W
back pain 2.2%
nasopharyngitis 2.2%
acanthosis nigricans 1.1%
NCT05372419 · Phase 3 · registry result, not featured evidence
250 mg Q2W
back pain 4.8%
blood creatine phosphokinase increased 4.8%
dermatitis atopic 4.8%
NCT05372419 · Phase 3 · registry result, not featured evidence
250 mg Q2W then 250 mg Q4W
conjunctivitis 3.6%
nasopharyngitis 3.6%
acne 1.8%
NCT05372419 · Phase 3 · registry result, not featured evidence
250 mg Q2W
dermatitis atopic 5.8%
upper respiratory tract infection 4.7%
injection site pain 3.5%
NCT05369403 · Phase 3 · registry result, not featured evidence
250 mg Q2W
concussion 5.6%
conjunctivitis 5.6%
covid-19 5.6%
NCT05369403 · Phase 3 · registry result, not featured evidence
250 mg Q2W then Q4W
joint swelling 4.9%
viral upper respiratory tract infection 4.9%
acne 2.4%
NCT05369403 · Phase 3 · registry result, not featured evidence
nasopharyngitis 12.7% (placebo 12.6%)
conjunctivitis 11.4% (placebo 1.8%)
conjunctivitis allergic 8.2% (placebo 2.7%)
NCT05149313 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 24.5% (placebo 12.6%)
conjunctivitis 11.8% (placebo 1.8%)
conjunctivitis allergic 8.5% (placebo 2.7%)
NCT05149313 · Phase 3 · registry result, not featured evidence
250 mg Q2W
conjunctivitis allergic 18.3% (placebo 4.9%)
covid-19 18.3% (placebo 2.4%)
pyrexia 18.3% (placebo 15.9%)
NCT04760314 · Phase 3 · registry result, not featured evidence
250mg Q2W
covid-19 21.8% (placebo 2.4%)
nasopharyngitis 12.7% (placebo 2.4%)
acne 10.9% (placebo 6.1%)
NCT04760314 · Phase 3 · registry result, not featured evidence
250mg Q2W
covid-19 19% (placebo 2.4%)
herpes simplex 19% (placebo 2.4%)
nasopharyngitis 14.3% (placebo 2.4%)
NCT04760314 · Phase 3 · registry result, not featured evidence
250mg Q2W
pyrexia 20.3% (placebo 15.9%)
conjunctivitis allergic 17.1% (placebo 4.9%)
conjunctivitis 9.8% (placebo 2.4%)
NCT04760314 · Phase 3 · registry result, not featured evidence
250mg Q4W
pyrexia 18.5% (placebo 15.9%)
conjunctivitis allergic 12.3% (placebo 4.9%)
conjunctivitis 6.2% (placebo 2.4%)
NCT04760314 · Phase 3 · registry result, not featured evidence
250 Q2W
covid-19 25% (placebo 2.4%)
abdominal pain 12.5% (placebo 1.2%)
acne 12.5% (placebo 6.1%)
NCT04760314 · Phase 3 · registry result, not featured evidence
Q4W
covid-19 21.2% (placebo 2.4%)
acne 18.2% (placebo 6.1%)
headache 18.2% (placebo 11%)
NCT04760314 · Phase 3 · registry result, not featured evidence
Q2W
pyrexia 34.4% (placebo 15.9%)
conjunctivitis allergic 12.5% (placebo 4.9%)
covid-19 12.5% (placebo 2.4%)
NCT04760314 · Phase 3 · registry result, not featured evidence
Q4W
covid-19 18.4% (placebo 2.4%)
pyrexia 18.4% (placebo 15.9%)
conjunctivitis allergic 13.2% (placebo 4.9%)
NCT04760314 · Phase 3 · registry result, not featured evidence
250 mg
covid-19 5.5% (placebo 3.9%)
dermatitis atopic 4.7% (placebo 6.3%)
headache 3.1% (placebo 0.8%)
NCT04626297 · Phase 3 · registry result, not featured evidence
250 mg
dermatitis atopic 12.6%
nasopharyngitis 9.7%
covid-19 9.2%
NCT04250350 · Phase 3 · registry result, not featured evidence
250 mg Q2W
nasopharyngitis 12% (placebo 3.8%)
headache 5.3% (placebo 5.8%)
injection site pain 5.3% (placebo 1.9%)
NCT03443024 · Phase 2 · registry result, not featured evidence
250 mg Q4W
upper respiratory tract infection 11.3% (placebo 5.8%)
fatigue 5% (placebo 0%)
diarrhoea 3.8% (placebo 0%)
NCT03443024 · Phase 2 · registry result, not featured evidence
125 mg Q4W
upper respiratory tract infection 8.2% (placebo 5.8%)
nasopharyngitis 5.5% (placebo 3.8%)
bacterial vaginosis 4.3% (placebo 0%)
NCT03443024 · Phase 2 · registry result, not featured evidence
f
nasopharyngitis 16.7% (placebo 7.6%)
injection site reaction 6.4% (placebo 1.3%)
dermatitis atopic 5.8% (placebo 5.1%)
NCT05958407 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 29 more results
injection site reaction 7.9% (placebo 1.3%)
nasopharyngitis 7.5% (placebo 7.6%)
covid-19 0% (placebo 0%)
NCT05958407 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
Q2W
dermatitis atopic 25.2% (placebo 38.3%)
viral upper respiratory tract infection 23.1% (placebo 20.9%)
conjunctivitis 7.1% (placebo 2%)
NCT03131648 · Phase 3
Q2W
viral upper respiratory tract infection 20.6% (placebo 20.9%)
dermatitis atopic 16.2% (placebo 38.3%)
headache 8.8% (placebo 5.1%)
NCT03131648 · Phase 3
Q4W
viral upper respiratory tract infection 23.7% (placebo 20.9%)
dermatitis atopic 18.4% (placebo 38.3%)
bronchitis 9.2% (placebo 2%)
NCT03131648 · Phase 3
Q2W + optional TCS
viral upper respiratory tract infection 25.4% (placebo 20.9%)
dermatitis atopic 21.8% (placebo 38.3%)
conjunctivitis 7.3% (placebo 2%)
NCT03131648 · Phase 3 · combination
Q2W
dermatitis atopic 16.4% (placebo 33.5%)
upper respiratory tract infection 10% (placebo 8.5%)
viral upper respiratory tract infection 8.3% (placebo 8.5%)
NCT03160885 · Phase 3
Q2W
upper respiratory tract infection 15.4% (placebo 8.5%)
dermatitis atopic 14.3% (placebo 33.5%)
viral upper respiratory tract infection 9.9% (placebo 8.5%)
NCT03160885 · Phase 3
Q4W
dermatitis atopic 15.7% (placebo 33.5%)
upper respiratory tract infection 10.1% (placebo 8.5%)
viral upper respiratory tract infection 6.7% (placebo 8.5%)
NCT03160885 · Phase 3
Q2W + Optional TCS
dermatitis atopic 20.4% (placebo 33.5%)
upper respiratory tract infection 11.6% (placebo 8.5%)
viral upper respiratory tract infection 10.4% (placebo 8.5%)
NCT03160885 · Phase 3 · combination
Q2W+TCS
viral upper respiratory tract infection 19% (placebo 17.1%)
dermatitis atopic 7.6% (placebo 4.9%)
conjunctivitis 3.8% (placebo 2.4%)
NCT03363854 · Phase 3 · combination
Q2W+TCS
viral upper respiratory tract infection 21.1% (placebo 17.1%)
dermatitis atopic 8.4% (placebo 4.9%)
headache 7.4% (placebo 2.4%)
NCT03363854 · Phase 3 · combination
Q2W+TCS
viral upper respiratory tract infection 17.4% (placebo 17.1%)
upper respiratory tract infection 10.1% (placebo 4.9%)
injection site reaction 7.2% (placebo 0%)
NCT03363854 · Phase 3 · combination
Q4W+TCS
viral upper respiratory tract infection 13% (placebo 17.1%)
headache 7.2% (placebo 2.4%)
injection site reaction 5.8% (placebo 0%)
NCT03363854 · Phase 3 · combination
Q2W+TCS
viral upper respiratory tract infection 19.4% (placebo 17.1%)
conjunctivitis 11.1% (placebo 2.4%)
headache 8.7% (placebo 2.4%)
NCT03363854 · Phase 3 · combination
150 Q2W
viral upper respiratory tract infection 19.4% (placebo 8.5%)
dermatitis atopic 12.2% (placebo 11.7%)
upper respiratory tract infection 8.2% (placebo 4.3%)
NCT03526861 · Phase 3
300 Q2W
viral upper respiratory tract infection 12.4% (placebo 8.5%)
upper respiratory tract infection 11.3% (placebo 4.3%)
dermatitis atopic 7.2% (placebo 11.7%)
NCT03526861 · Phase 3
150 Q2W
pharyngitis 25% (placebo 4.3%)
acne 8.3% (placebo 4.3%)
acute sinusitis 8.3% (placebo 1.1%)
NCT03526861 · Phase 3
150 Q4W
dermatitis atopic 14.3% (placebo 11.7%)
acne 7.1% (placebo 4.3%)
attention deficit/hyperactivity disorder 7.1% (placebo 0%)
NCT03526861 · Phase 3
300 Q2W
influenza 18.2% (placebo 1.1%)
upper respiratory tract infection 18.2% (placebo 4.3%)
viral upper respiratory tract infection 18.2% (placebo 8.5%)
NCT03526861 · Phase 3
300 Q4W
bacterial vaginosis 7.7% (placebo 0%)
conjunctivitis 7.7% (placebo 0%)
inappropriate schedule of drug administration 7.7% (placebo 0%)
NCT03526861 · Phase 3
300 Q2W
viral upper respiratory tract infection 18.8% (placebo 8.5%)
upper respiratory tract infection 10.7% (placebo 4.3%)
dermatitis atopic 8.1% (placebo 11.7%)
NCT03526861 · Phase 3 · combination
nasopharyngitis 22.2%
atopic dermatitis 21%
covid-19 17.6%
NCT03587805 · Phase 3 · registry result, not featured evidence
injection site reaction 5.9%
dermatitis atopic 4.4%
conjunctivitis 2.9%
NCT05194540 · Phase 3 · registry result, not featured evidence · combination
viral upper respiratory tract infection 2.7% (placebo 1.2%)
arthralgia 1.3% (placebo 0%)
cholelithiasis 1.3% (placebo 0%)
NCT03761537 · Phase 3 · registry result, not featured evidence · combination
viral upper respiratory tract infection 26.8% (placebo 1.2%)
headache 15.2% (placebo 0%)
upper respiratory tract infection 7.2% (placebo 0%)
NCT03761537 · Phase 3 · registry result, not featured evidence · combination
dermatitis atopic 11.2% (placebo 12.1%)
viral upper respiratory tract infection 9.3% (placebo 2.8%)
headache 2.8% (placebo 1.9%)
NCT03562377 · Phase 2 · registry result, not featured evidence
nasopharyngitis 22% (placebo 11.8%)
upper respiratory tract infection 10% (placebo 9.8%)
dermatitis atopic 6% (placebo 7.8%)
NCT02347176 · Phase 2 · registry result, not featured evidence
nasopharyngitis 15.7% (placebo 11.8%)
upper respiratory tract infection 11.8% (placebo 9.8%)
headache 7.8% (placebo 3.9%)
NCT02347176 · Phase 2 · registry result, not featured evidence
nasopharyngitis 25% (placebo 11.8%)
headache 7.7% (placebo 3.9%)
upper respiratory tract infection 7.7% (placebo 9.8%)
NCT02347176 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for both studies.
  2. bTreatment context has not been resolved for both arms.
  3. cThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  4. dTrial phases differ: Phase 2 versus Phase 3.
  5. ePopulation comparability has not been reviewed for 35 of these studies.
  6. fPopulation comparability has not been reviewed for 41 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

lebrikizumab

Pruritus NRS -60.63% (n=50) vs 4.26% (n=22) placebo @ 16wk250 mg Q2W
percent change · % of baseline
NCT03443024 · Phase 2 · registry result, not featured evidence
show 5 more results
-49.6% (n=56) vs 4.26% (n=22) placebo @ 16wk250 mg Q4W
NCT03443024 · Phase 2 · registry result, not featured evidence
-35.94% (n=55) vs 4.26% (n=22) placebo @ 16wk125 mg Q4W
NCT03443024 · Phase 2 · registry result, not featured evidence
-45.48% (n=276) vs -15.06% (n=136) placebo @ 16wkQ2W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-36.56% (n=281) vs -9.02% (n=146) placebo @ 16wkQ2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-50.68% (n=139) vs -35.47% (n=63) placebo @ 16wk
NCT04250337 · Phase 3 · combination
Pruritus NRS 4-point Reduction 45.9% (n=263) vs 13% (n=130) placebo @ 16wkQ2W
responder rate · % of participants
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 15 more results
49% (n=244) vs 13.7% (n=123) placebo @ 16wkQ2W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
2.3% (n=263) vs 0.8% (n=130) placebo @ 1wkQ2W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
6.1% (n=263) vs 0.9% (n=130) placebo @ 2wkQ2W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
21.5% (n=263) vs 2.3% (n=130) placebo @ 4wkQ2W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
2.5% (n=244) vs 0.8% (n=123) placebo @ 1wkQ2W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
6.6% (n=244) vs 0.9% (n=123) placebo @ 2wkQ2W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
23.1% (n=244) vs 2.4% (n=123) placebo @ 4wkQ2W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
50.6% (n=130) vs 31.9% (n=57) placebo @ 16wk
NCT04250337 · Phase 3 · combination
46.8% (n=124) vs 26.4% (n=53) placebo @ 16wk
NCT04250337 · Phase 3 · combination
23.5% (n=130) vs 9.3% (n=57) placebo @ 4wk
NCT04250337 · Phase 3 · combination
8.5% (n=130) vs 7.1% (n=57) placebo @ 2wk
NCT04250337 · Phase 3 · combination
3.8% (n=130) vs 1.8% (n=57) placebo @ 1wk
NCT04250337 · Phase 3 · combination
23.4% (n=124) vs 7.5% (n=53) placebo @ 4wk
NCT04250337 · Phase 3 · combination
8.9% (n=124) vs 7.5% (n=53) placebo @ 2wk
NCT04250337 · Phase 3 · combination
4% (n=124) vs 1.9% (n=53) placebo @ 1wk
NCT04250337 · Phase 3 · combination
BSA -27.55% (n=110) vs -19.34% (n=85) placebo @ 16wk250 mg
absolute change · percentage points
NCT04626297 · Phase 3 · registry result, not featured evidence
show 5 more results
-24.3% (n=59) vs -17.4% (n=24) placebo @ 16wk250 mg Q2W
NCT03443024 · Phase 2 · registry result, not featured evidence
-24.9% (n=62) vs -17.4% (n=24) placebo @ 16wk250 mg Q4W
NCT03443024 · Phase 2 · registry result, not featured evidence
-19.6% (n=59) vs -17.4% (n=24) placebo @ 16wk125 mg Q4W
NCT03443024 · Phase 2 · registry result, not featured evidence
-30.2% (n=235) vs -11.7% (n=77) placebo @ 16wkQ2W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-30.2% (n=213) vs -14% (n=77) placebo @ 16wkQ2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
DLQI 4-Point Improvement 71.5% (n=239) vs 32.4% (n=121) placebo @ 16wkQ2W
responder rate · % of participants
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 3 more results
75.6% (n=226) vs 33.8% (n=116) placebo @ 16wkQ2W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
65.4% (n=218) vs 32.8% (n=118) placebo @ 16wkQ2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
66.3% (n=215) vs 33.6% (n=115) placebo @ 16wkQ2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
Sleep-loss -64.69% (n=38) vs -20.24% (n=14) placebo @ 16wk250 mg Q2W
percent change · % of baseline
NCT03443024 · Phase 2 · registry result, not featured evidence
show 5 more results
-53.03% (n=33) vs -20.24% (n=14) placebo @ 16wk250 mg Q4W
NCT03443024 · Phase 2 · registry result, not featured evidence
-48.68% (n=38) vs -20.24% (n=14) placebo @ 16wk125 mg Q4W
NCT03443024 · Phase 2 · registry result, not featured evidence
-48.33% (n=269) vs -15.99% (n=132) placebo @ 16wkQ2W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-48.37% (n=281) vs -11.29% (n=146) placebo @ 16wkQ2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-57.03% (n=134) vs -36.89% (n=62) placebo @ 16wk
NCT04250337 · Phase 3 · combination
Sleep-Loss -1.35 vs -0.87 placebo score @ 16wk250 mg
absolute change · score
NCT04626297 · Phase 3 · registry result, not featured evidence
show 3 more results
-1.13 vs -0.38 placebo score @ 16wkQ2W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-1.05 vs -0.35 placebo score @ 16wkQ2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-1.1 vs -0.8 placebo score @ 16wk
NCT04250337 · Phase 3 · combination
Sleep-loss 2-point Improvement 39% (n=195) vs 4.7% (n=91) placebo @ 16wkQ2W
responder rate · % of participants
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
SCORAD -46.93% (n=276) vs -16.64% (n=138) placebo @ 16wkQ2W
percent change · % of baseline
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 4 more results
-44.57% (n=281) vs -13.81% (n=146) placebo @ 16wkQ2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-73.89% (n=53) vs -67.6% (n=27) placebo @ 52wk250 Q4W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-73.85% (n=51) vs -67.6% (n=27) placebo @ 52wk250 Q2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-55.04% (n=140) vs -37.35% (n=65) placebo @ 16wk
NCT04250337 · Phase 3 · combination
Pruritus NRS 4-point Sustained 80.4% (n=29) vs 65.4% (n=17) placebo @ 52wk250 Q4W
responder rate · % of participants
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 15 more results
81.2% (n=38) vs 65.4% (n=17) placebo @ 52wk250 Q2W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
83.3% (n=28) vs 65.4% (n=17) placebo @ 52wk250 Q4W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
81.2% (n=38) vs 65.4% (n=17) placebo @ 52wk250 Q2W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
39.8% (n=253) vs 11.5% (n=134) placebo @ 16wkQ2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
41.6% (n=234) vs 11.8% (n=122) placebo @ 16wkQ2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0.4% (n=253) vs 0% (n=134) placebo @ 1wkQ2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
3.6% (n=253) vs 0.7% (n=134) placebo @ 2wkQ2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
16.8% (n=253) vs 3% (n=134) placebo @ 4wkQ2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0.4% (n=234) vs 0% (n=122) placebo @ 1wkQ2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
3.9% (n=234) vs 0.8% (n=122) placebo @ 2wkQ2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
18.1% (n=234) vs 3.3% (n=122) placebo @ 4wkQ2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
88.1% (n=36) vs 67.6% (n=11) placebo @ 52wk250 Q4W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
90.3% (n=23) vs 67.6% (n=11) placebo @ 52wk250 Q2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
87.4% (n=34) vs 67.6% (n=11) placebo @ 52wk250 Q4W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
94.4% (n=22) vs 67.6% (n=11) placebo @ 52wk250 Q2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
EQ-5D-5L Index 0.2 vs 0 placebo score @ 16wkQ2W
absolute change · score
Health State Index UK
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 1 more result
0.1 vs 0 placebo score @ 16wkQ2W
Health State Index UK
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
EQ-5D-5L VAS 10.4 vs 2.1 placebo score @ 16wkQ2W
absolute change · score
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
PROMIS Anxiety -3.87 vs -2.8 placebo T-score @ 16wkQ2W
absolute change · T-score
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 3 more results
-3.91 vs -0.6 placebo T-score @ 16wkQ2W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-2.79 vs 0.12 placebo T-score @ 16wkQ2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-3.18 vs -0.45 placebo T-score @ 16wkQ2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3

+ 74 further endpoints in the CSV export.

tralokinumab

IGA-AHE 0 1 40% (n=156) vs 10.6% (n=79) placebo @ 16wk
responder rate · % of participants
NCT05958407 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
IGA-AHE Improvement 2 40.1% (n=156) vs 10.6% (n=79) placebo @ 16wk
absolute value · percentage points
NCT05958407 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
HECSI-75 64.1% (n=156) vs 33.8% (n=79) placebo @ 16wk
responder rate · % of participants
NCT05958407 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
HECSI-50 79.7% (n=156) vs 50.7% (n=79) placebo @ 16wk
responder rate · % of participants
NCT05958407 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
HECSI-90 41.7% (n=156) vs 10.9% (n=79) placebo @ 16wk
responder rate · % of participants
NCT05958407 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
HECSI -69.9% (n=156) vs -31.4% (n=79) placebo @ 16wk
percent change · % of baseline
NCT05958407 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
HESD Itch Improvement 4 47.3% (n=153) vs 20.7% (n=78) placebo @ 16wk
absolute value · percentage points
NCT05958407 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
HESD Itch -51.1% (n=155) vs -23.7% (n=78) placebo @ 16wk
percent change · % of baseline
NCT05958407 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
HESD Pain Improvement 4 45.3% (n=138) vs 13.3% (n=73) placebo @ 16wk
absolute value · percentage points
NCT05958407 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
HESD Pain -60.1% (n=153) vs -13.2% (n=78) placebo @ 16wk
percent change · % of baseline
NCT05958407 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
HEIS -64.9% (n=154) vs -28.5% (n=77) placebo @ 16wk
percent change · % of baseline
NCT05958407 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
DLQI -60.9% (n=154) vs -21% (n=77) placebo @ 16wk
percent change · % of baseline
NCT05958407 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3

+ 32 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: lebrikizumab's landscape · tralokinumab's landscape